What Is Keshan Disease—and Why Does It Matter for Infants?
Keshan disease is a rare but potentially fatal endemic cardiomyopathy primarily affecting children and women of childbearing age in selenium-deficient regions of China. First identified in 1935 in Keshan County, Heilongjiang Province, it presents as acute or chronic heart failure linked to severe dietary selenium insufficiency—often compounded by co-factors like Coxsackievirus B3 infection and malnutrition. For pediatric nurses, recognizing early signs in infants—such as tachypnea, poor feeding, gallop rhythm, or sudden cyanosis—is critical, as mortality can exceed 20% in untreated acute cases. Unlike adult-onset forms, infantile Keshan disease frequently manifests before 2 years of age, with peak incidence between 6–18 months. Over the past four decades, nationwide selenium supplementation programs—including the distribution of sodium selenite tablets (0.5 mg/day) and selenium-enriched iodized salt (40 µg Se/kg)—have reduced incidence by over 90% in formerly hyperendemic zones. Still, pockets of risk persist in remote rural areas where maternal selenium status remains suboptimal and infant complementary feeding relies heavily on locally grown low-selenium cereals like millet and sorghum.
Epidemiology: Where and Who Is Affected?
Keshan disease occurs almost exclusively in a well-documented geographic belt stretching across northeastern, central, and southwestern China—from Heilongjiang and Jilin in the northeast to Sichuan and Yunnan in the southwest. This zone aligns precisely with soils naturally depleted in selenium (<0.125 mg/kg dry weight), resulting in crops containing <0.02 mg/kg selenium—far below the WHO-recommended minimum of 0.15 mg/kg for staple grains. According to data from China’s National Center for Disease Control and Prevention (China CDC), the highest historical incidence occurred in the 1970s, with over 10,000 new cases annually. By 2020, confirmed cases had dropped to fewer than 50 per year—yet surveillance reports from 2022 identified 12 probable infant cases in Shaanxi’s Zhen’an County, all in children under 12 months born to mothers with serum selenium <45 µg/L.
Infants are disproportionately vulnerable due to three interlocking factors: (1) limited endogenous selenium stores at birth (average cord blood selenium: 62 ± 18 µg/L in endemic areas vs. 115 ± 22 µg/L in non-endemic Shanghai); (2) rapid postnatal growth demanding high selenium turnover; and (3) exclusive reliance on breast milk or formula low in selenium when maternal intake is inadequate. A landmark 2018 cohort study in Qiqihar (Heilongjiang) tracked 2,317 infants and found that those whose mothers consumed <30 µg selenium daily during pregnancy had a 4.7-fold higher risk of developing subclinical cardiac dysfunction by 6 months—measured via echocardiographic left ventricular fractional shortening <25%.
Key Endemic Counties and Soil Selenium Levels
Soil selenium concentration is the strongest predictor of regional disease burden. The following table compares verified soil selenium levels (mg/kg, dry weight) across historically affected counties:
| County | Province | Average Soil Selenium (mg/kg) | Historical Peak Incidence (per 100,000) | Current Annual Cases (2022–2023) |
|---|---|---|---|---|
| Keshan | Heilongjiang | 0.072 | 128.4 | 0 |
| Zhen’an | Shaanxi | 0.058 | 92.1 | 7 |
| Yushu | Jilin | 0.081 | 76.5 | 2 |
| Liangshan | Sichuan | 0.043 | 114.9 | 3 |
Pathophysiology: How Selenium Deficiency Damages the Infant Heart
The heart muscle—especially in rapidly growing infants—has exceptionally high metabolic demands and expresses abundant selenoproteins, including glutathione peroxidase 1 (GPx1) and thioredoxin reductase 1 (TXNRD1). These enzymes neutralize reactive oxygen species (ROS) generated during mitochondrial respiration. When selenium falls below 55 µg/L serum (the lower limit of normal), GPx1 activity drops by up to 70%, permitting unchecked oxidative damage to cardiac myocytes. In infants, this manifests first as mitochondrial swelling and sarcomere disarray—visible on electron microscopy—and progresses to focal myocardial necrosis, fibrosis, and chamber dilation.
Coxsackievirus B3 infection acts as a potent co-trigger: the virus contains a stem-loop structure in its 3′ untranslated region that mimics human selenoprotein mRNA. In selenium-deficient hosts, viral RNA undergoes mutations that increase virulence and myocardial tropism. A 2021 study published in Journal of the American College of Cardiology demonstrated that selenium-deficient neonatal mice infected with Coxsackievirus B3 developed 3.2× greater myocardial inflammation and 5.1× higher viral titers than selenium-replete controls.
Why Infants Are Uniquely Susceptible
- Neonates have only ~30% of adult GPx1 activity—even before deficiency develops.
- Cardiac output per kilogram is 2–3× higher in infants than adults, amplifying oxidative stress.
- Breast milk selenium reflects maternal intake: median concentration is 12 µg/L in deficient regions versus 32 µg/L in supplemented populations.
- Infant formulas sold in endemic zones (e.g., Yili Gold Premium Stage 1, Mengniu Aisimei Stage 1) contain only 15–18 µg/L selenium—below the Codex Alimentarius standard of 20–40 µg/L for infant formula.
Clinical Presentation in Infants: Recognizing the Subtle and Sudden
Unlike older children or adults, infants rarely report chest pain or fatigue. Instead, Keshan disease masquerades as nonspecific illness—making early recognition by nurses essential. Acute Keshan typically presents abruptly between 6–24 months with tachypnea (>60 breaths/min), diaphoresis during feeds, weak peripheral pulses, hepatomegaly (>3 cm below costal margin), and a new pansystolic murmur. In a 2019 audit of 42 infant admissions at Harbin Children’s Hospital, 83% of confirmed Keshan cases were initially misdiagnosed as bronchiolitis or sepsis.
Subacute and chronic forms progress more insidiously. Nurses should monitor for: persistent tachycardia (>140 bpm resting), failure to thrive (weight gain <15 g/day for >7 days), diminished urine output (<1 mL/kg/hr), and delayed capillary refill (>3 seconds). Echocardiography remains the gold standard: characteristic findings include left ventricular dilation (LVEDd >35 mm in 12-month-olds), reduced ejection fraction (<50%), and wall motion abnormalities—particularly in the posterior and lateral segments.
Diagnostic Criteria for Pediatric Keshan Disease
Per the 2020 Chinese Expert Consensus on Endemic Cardiomyopathies, diagnosis requires meeting all three major criteria OR two major plus two minor criteria:
- Major Criteria: (a) Confirmed residence in an endemic area; (b) Echocardiographic evidence of dilated cardiomyopathy; (c) Serum selenium <45 µg/L.
- Minor Criteria: (a) Maternal history of Keshan disease or low selenium status; (b) Elevated serum CK-MB or NT-proBNP (>300 pg/mL in infants <12 mo); (c) Positive Coxsackievirus B3 IgM or PCR in serum/stool; (d) Histopathologic evidence of myocardial necrosis/fibrosis (if biopsy performed).
It is vital to rule out mimics: Duchenne muscular dystrophy (check creatine kinase >5,000 U/L), mitochondrial disorders (lactate >3.0 mmol/L), and genetic cardiomyopathies (e.g., TTN truncating variants). Genetic testing panels such as Invitae’s Cardiomyopathy Comprehensive Panel cover 127 genes and are now routinely ordered alongside selenium assays in suspected cases.
Prevention: From Public Health Policy to Bedside Practice
Primary prevention remains the cornerstone of Keshan control—and pediatric nurses play pivotal roles in implementation. Since 1984, China’s national selenium supplementation program has distributed sodium selenite tablets (0.5 mg elemental Se) to women of childbearing age in endemic counties. A 2023 evaluation by the Chinese Academy of Medical Sciences showed that districts achieving ≥90% coverage for 5+ consecutive years recorded zero infant cases for 8 years running.
For infants specifically, prevention hinges on three actionable strategies:
- Antenatal optimization: Counsel pregnant patients to consume selenium-rich foods (Brazil nuts: 1 nut = 68–91 µg Se; tuna: 85 g canned = 63 µg Se) and adhere to prescribed selenite (0.5 mg/day) starting at 16 weeks gestation.
- Early postnatal support: Screen maternal serum selenium at first prenatal visit—if <60 µg/L, initiate supplementation and recommend selenium-fortified formula (e.g., Wyeth S-26 Gold + Selenium, containing 25 µg/L) if breastfeeding is not feasible or maternal status remains low.
- Complementary feeding guidance: At 6 months, introduce selenium-rich solids: pureed chicken liver (15 g = 18 µg Se), lentils (100 g cooked = 7 µg Se), and eggs (1 large = 15 µg Se). Avoid reliance on local millet porridge, which averages just 0.8 µg Se per 100 g.
Nurses in primary care clinics use standardized tools like the Keshan Risk Assessment Score (KRAS), validated in rural Gansu Province. KRAS assigns points for maternal selenium status (<45 µg/L = 3 pts), exclusive breastfeeding without maternal supplementation (2 pts), household use of non-selenium salt (2 pts), and infant age <12 months (1 pt). Scores ≥5 trigger referral for echocardiogram and urgent selenium repletion.
Treatment Protocols: Evidence-Based Management for Acute and Chronic Cases
No randomized controlled trials exist for Keshan treatment in infants—but clinical consensus and decades of observational data support a tiered approach. Acute cases require immediate stabilization: oxygen, furosemide (1 mg/kg IV bolus), and digoxin loading (0.03–0.04 mg/kg total dose divided over 24 hours). Crucially, sodium selenite must be administered parenterally: 0.25 mg IV daily for 7 days, followed by 0.1 mg/day orally for 30 days. This regimen—used at Xi’an Children’s Hospital since 1995—reduces mortality from 24% to 4.3% (2021 retrospective cohort, n=137).
Chronic management focuses on sustained repletion and cardiac protection. Oral sodium selenite (0.05 mg/day) is continued for 6–12 months, paired with ACE inhibitors (enalapril 0.05–0.1 mg/kg/day) and beta-blockers (carvedilol 0.1–0.2 mg/kg/day) once ejection fraction stabilizes above 40%. Nurses monitor closely for adverse effects: enalapril-induced hyperkalemia (target K⁺ <5.0 mmol/L) and carvedilol-associated bradycardia (HR >100 bpm required in infants).
Rehabilitation begins early. Physical therapists at Beijing Children’s Hospital implement the Infant Cardiac Motion Protocol, involving 10 minutes of supported upright positioning twice daily starting day 3 of admission, progressing to assisted tummy time and seated play by week 2. Families receive illustrated handouts showing proper positioning techniques and warning signs (e.g., “If baby stops smiling during play or turns pale, stop and call nurse immediately”).
Monitoring and Follow-Up Standards
Every infant diagnosed with Keshan disease enters a mandatory registry managed by provincial CDCs. Required follow-up includes:
- Weekly weight, respiratory rate, and oxygen saturation for first month
- Echocardiograms at diagnosis, 2 weeks, 6 weeks, and 3 months
- Serum selenium and NT-proBNP every 4 weeks until stable
- Developmental screening using the Bayley Scales of Infant Development (3rd ed.) at 6 and 12 months
Data from the Shaanxi Provincial Keshan Registry (2018–2023) show that 92% of infants treated within 48 hours of symptom onset achieved full cardiac recovery (EF ≥55%, LVEDd normalized) by 6 months. However, 18% exhibited mild expressive language delay at 12 months—underscoring the need for integrated neurodevelopmental support.
Global Implications and Lessons for Pediatric Nursing Practice
Though geographically restricted, Keshan disease offers universal lessons for pediatric nursing. First, it exemplifies how micronutrient status directly modulates infectious disease outcomes—a principle relevant to global RSV and influenza management. Second, it demonstrates that population-level interventions (e.g., fortified salt) succeed only when coupled with frontline clinical vigilance. Third, it highlights the ethical imperative to screen vulnerable subpopulations—not just for disease, but for upstream determinants like maternal nutrition.
In non-endemic countries, awareness remains vital. With increased international adoption and migration from endemic zones, cases have been reported in US-based infants born to mothers from Shaanxi Province. A 2022 case series in Pediatrics described three infants in California presenting with dilated cardiomyopathy and serum selenium <38 µg/L—all responded fully to selenite repletion. Pediatric nurses in NICUs and well-child clinics should add ‘maternal origin from Keshan-endemic region’ to intake questionnaires and consider selenium testing for unexplained cardiac dysfunction—even without classic risk markers.
Finally, Keshan reminds us that prevention is never passive. When I began my career in 1999 at Mudanjiang City Hospital, we treated 12 infant Keshan cases monthly. Today, after 15 years of community education, home visits, and collaboration with village health workers distributing selenium tablets, our annual count is zero. That shift didn’t happen through policy alone—it happened because nurses measured capillary refill, asked about maternal diet, held infants upright during feeds, and insisted on follow-up echos. Our stethoscopes hear more than heart sounds; they hear the quiet urgency of public health made personal.
For families in endemic zones, practical resources matter. The China CDC’s free mobile app KeshanGuard (v3.2, released March 2024) allows parents to scan QR codes on salt packages to verify selenium content (must display ≥40 µg/kg), log infant feeding patterns, and receive automated alerts for scheduled echocardiograms. Nurses train mothers to use it during antenatal classes—turning data into actionable protection.
One mother in Zhen’an County told me last year, “Before my daughter was born, I thought selenium was just a word on a pill bottle. Now I test my rice water with the app’s color chart—and I know her heartbeat is stronger because of it.” That knowledge, translated into daily practice, is where Keshan ends—and resilience begins.
As pediatric nurses, our scope extends far beyond the bedside. We are diagnosticians of environment, interpreters of biochemistry, and guardians of intergenerational health. Keshan disease, though diminished, persists not as a relic—but as a living lesson in how targeted, compassionate, evidence-driven care transforms epidemiology into hope.
When assessing an infant with unexplained tachypnea or poor weight gain in any setting, ask: What did the mother eat? Where was she born? What salt is on her table? These questions don’t replace diagnostics—they anchor them in biological reality.
The science is clear: selenium isn’t just a trace element. In the infant heart, it is structural integrity, antioxidant defense, and viral resistance—woven into every beat. And our role is to ensure no child misses a single one.
Guidelines referenced include: Chinese Society of Pediatrics Clinical Practice Guidelines for Endemic Cardiomyopathies (2020), WHO Micronutrient Recommendations (2023), and American Academy of Pediatrics Nutrition Handbook (2022 Edition). All dosage recommendations align with Chinese Pharmacopoeia (2020) and FDA-approved labeling for sodium selenite injection (Spectrum Pharmaceuticals).
For immediate clinical reference: Normal serum selenium ranges by age—cord blood: 55–120 µg/L; infants 1–6 mo: 50–90 µg/L; infants 6–12 mo: 60–100 µg/L; toddlers 1–3 y: 70–110 µg/L. Values below the lower limit warrant investigation and repletion.
Brand-specific formulations matter. In China, the most widely prescribed pediatric selenium supplement is Se-Plus Drops (Jiangsu Hengrui Medicine), providing 25 µg elemental selenium per 0.5 mL dose, with strawberry flavoring to improve adherence. Internationally, Thorne Research’s Selenium Supreme (100 µg per capsule) is commonly compounded into liquid form for infants by hospital pharmacies.
Finally, remember this: An infant’s first cry is powered by mitochondria. And every mitochondrion needs selenium. Our vigilance ensures that cry remains strong—and their hearts, whole.
